Curr Probl Cardiol. 2013 Sep;38(9):365-409. doi: 10.1016/j.cpcardiol.2013.06.003.
Increased life expectancy has led to a higher prevalence of calcific aortic valve disease. Both ends of the disease spectrum-sclerosis of the aortic valve without hemodynamic obstruction and the late stage of aortic valve stenosis (AS)-have been associated with increased morbidity and mortality. This raises the question of the prognostic contribution of atherosclerotic diseases and other comorbidities as opposed to the hemodynamic effect of obstructive AS. Hence, the evaluation of asymptomatic patients with mild or moderate AS without comorbidities is of major interest. In the Simvastatin and Ezetimibe in Aortic Stenosis study, with the exception of hypertension, comorbidities were excluded, thus allowing an analysis of the effect of pure AS as well as the effect of hypertension on the progression and outcome of AS. We discuss the results that emerged from this large European prospective study and relate these to the published literature.
预期寿命的延长导致了钙化性主动脉瓣疾病的高发。该疾病谱的两端——无血流动力学阻塞的主动脉瓣硬化和晚期主动脉瓣狭窄（AS）——都与发病率和死亡率的增加有关。这就提出了一个问题，即与阻塞性 AS 的血流动力学效应相比，动脉粥样硬化性疾病和其他合并症的预后贡献如何。因此，对无合并症的轻度或中度 AS 无症状患者的评估具有重要意义。在辛伐他汀和依折麦布治疗主动脉瓣狭窄研究中，除了高血压之外，还排除了合并症，因此可以分析单纯 AS 的影响以及高血压对 AS 进展和结局的影响。我们讨论了这项大型欧洲前瞻性研究得出的结果，并将这些结果与已发表的文献联系起来。
